Juvenile dermatomyositis: novel treatment approaches and outcomes
| Autor: | Clarissa Pilkington, Lucy R. Wedderburn, Giulia C. Varnier |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
030203 arthritis & rheumatology
medicine.medical_specialty International studies business.industry Biopsy Outcome measures medicine.disease Dermatomyositis 03 medical and health sciences 0302 clinical medicine Rheumatology Outcome Assessment Health Care medicine Humans Immunologic Factors 030212 general & internal medicine Muscle Skeletal Rituximab Intensive care medicine business Glucocorticoids Juvenile dermatomyositis |
| Zdroj: | Current Opinion in Rheumatology. 30:650-654 |
| ISSN: | 1531-6963 1040-8711 |
| DOI: | 10.1097/bor.0000000000000538 |
| Popis: | The aim of this article is to provide a summary of the recent therapeutic advances and the latest research on outcome measures for juvenile dermatomyositis (JDM).Several new international studies have developed consensus-based guidelines on diagnosis, outcome measures and treatment of JDM to standardize and improve patient care. Myositis-specific antibodies together with muscle biopsy histopathology may help the clinician to predict disease outcome. A newly developed MRI-based scoring system has been developed to standardize the use of MRI in assessing disease activity in JDM. New data regarding the efficacy and safety of rituximab, especially for skin disease, and cyclophosphamide in JDM support the use of these medications for severe refractory cases.International network studies, new biomarkers and outcome measures have led to significant progress in understanding and managing the rare inflammatory myositis conditions such as JDM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|